Form 4: Stoke Therapeutics Director Arthur Levin Converts Restricted Stock Units to Common Shares

Stoke Therapeutics, Inc. Director Arthur A. Levin acquired 1,210 shares of common stock through the conversion of Restricted Stock Units as part of a pre-arranged trading plan.

Summary

• Director Arthur A. Levin acquired 1,210 shares of Stoke Therapeutics, Inc. common stock on June 30, 2025.
• The acquisition resulted from the conversion of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Arthur A. Levin directly holds 2,420 shares of common stock.
• Additionally, 17,979 shares of common stock are indirectly beneficially owned through the Butler-Levin Revocable Trust.
• The RSUs vest quarterly, with 1/4 of the total award vesting on the last day of March, June, September, and December, contingent on continued service.
• The transaction was executed under a Rule 10b5-1(c) trading plan.

Sentiment

Score: 7

Explanation: The document reports a routine, pre-scheduled insider transaction (RSU vesting and conversion) which is generally a neutral to slightly positive event, indicating continued director service and equity accumulation. The use of a 10b5-1 plan adds to transparency.

Positives

• Conversion of Restricted Stock Units into common stock indicates a vesting event, reflecting continued service of a director.
• The transaction was conducted under a Rule 10b5-1(c) plan, demonstrating a pre-planned and transparent approach to insider trading.

Future Outlook

The vesting schedule for Restricted Stock Units indicates future quarterly vesting events on the last day of March, June, September, and December, contingent on the reporting person's continued service to the issuer.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting and conversion of equity compensation. It does not provide broader industry context or trends. Such transactions are common across all publicly traded companies as part of executive and director compensation plans.

Comparison to Industry Standards

• This is a standard insider transaction report (Form 4) for the vesting of Restricted Stock Units, which is a common form of equity compensation for directors and executives across various industries, including biotechnology.
• The $0 acquisition price for RSU conversion is standard practice.
• The use of a Rule 10b5-1 plan aligns with best practices for insiders to manage their equity holdings transparently and avoid accusations of trading on material non-public information.
• No specific comparable companies or projects are mentioned in the document to allow for a detailed comparison.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 17,979 shares of common stock through the Butler-Levin Revocable Trust, where Arthur A. Levin, Ph.D., serves as Trustee.

Stakeholder Impact

• Shareholders: Increased direct and indirect insider ownership, which can be viewed positively as it aligns management interests with shareholder interests. The transaction being under a 10b5-1 plan provides transparency.

Next Steps

• Future quarterly vesting of remaining Restricted Stock Units on the last day of March, June, September, and December, subject to continued service.

Key Dates

Keywords

Stoke Therapeutics, STOK, Arthur A. Levin, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Equity Compensation, Rule 10b5-1 Plan